NAGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Niagen Bioscience Inc (NAGE) is not a strong buy at the moment for a beginner, long-term investor. While the company has shown revenue growth, its declining net income, EPS, and mixed technical indicators suggest a cautious approach. Additionally, the lack of significant positive catalysts and the bearish short-term stock trend further support holding off on immediate investment.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 49.047, and moving averages are converging, showing no clear trend. Key support is at 4.452, and resistance is at 4.983. The stock is trading near its pivot point of 4.717, suggesting indecision in the market.
Gross margin improved to 64.14%, up 2.66% YoY. Analysts maintain a Buy rating with a price target of $13, indicating potential upside.
The stock has a 60% chance of declining in the next day (-1.55%), week (-3.97%), and month (-20.65%). No significant hedge fund or insider trading activity. Congress trading data is unavailable.
In Q4 2025, revenue increased to $33.84M (+16.19% YoY), but net income dropped to $4.13M (-42.44% YoY), and EPS fell to 0.05 (-44.44% YoY). Gross margin improved to 64.14% (+2.66% YoY), indicating operational efficiency despite declining profitability.
Canaccord analyst Susan Anderson lowered the price target to $13 from $14 but maintained a Buy rating, citing strong demand in the core business and potential upside in the injectable business.
